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Abstract 
Cholinesterase inhibitors, the current frontline symptomatic treatment for Alzheimer’s 
disease (AD), are associated with low efficacy and adverse effects. M1 muscarinic 
acetylcholine receptors (M1 mAChRs) represent a potential alternative therapeutic 
target; however, drug discovery programmes focused on this G protein-coupled 
receptor (GPCR) have failed largely due to cholinergic adverse responses. 
Employing novel chemogenetic and phosphorylation-deficient, G protein-biased, 
mouse models, paired with a tool-box of probe molecules, we establish previously 
unappreciated pharmacologically targetable M1 mAChR neurological processes, 
including anxiety-like behaviours and hyper-locomotion. By mapping the upstream 
signalling pathways regulating these responses, we determine the importance of 
receptor phosphorylation-dependent signalling in driving clinically relevant outcomes 
and in controlling adverse effects including “epileptic-like” seizures. We conclude that 
M1 mAChR ligands that promote receptor-phosphorylation dependent signalling 
would protect against cholinergic-adverse effects in addition to driving beneficial 
responses such as learning and memory and anxiolytic behaviour relevant for the 
treatment of AD.  
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Introduction 
Alzheimer’s disease (AD) is the most common form of dementia affecting ~850,000 
people in the UK alone, and 50 million worldwide. Like many forms of dementia, AD 
is associated with a spectrum of symptoms that includes memory loss but also 
behavioural disturbances, such as anxiety and agitation. A single treatment strategy 
that might address the multiple components of AD has yet to emerge. Rather the 
underlying basis of symptomatic treatment of AD is centred on addressing cognitive 
deficits by the restoration of cholinergic transmission via the inhibition of 
acetylcholinesterase, the enzyme responsible for the breakdown of acetylcholine 1. 
However, the efficacy of this treatment is limited by serious dose-related cholinergic 
adverse responses due primarily to the whole-body up-regulation of cholinergic 
systems, both central and peripheral 2,3.  
A widely considered alternative strategy has been to target the M1 mAChR, one of 
five members (M1-M5) of a family of G protein-coupled receptors (GPCRs) that 
respond to acetylcholine and that shows pro-cognitive effects in preclinical animal 
studies 4-8.  However, despite some positive indications of efficacy in clinical trials, 
the M1/M4 preferring orthosteric agonist xanomeline9 and the bitopic agonist 
GSK1034702 10-12, failed due to adverse cholinergic effects. An alternative strategy, 
designed to reduce adverse responses by increasing selectivity for the M1 mAChR, 
is to target non-conserved allosteric sites which would positively modulate receptor 
activity, so called positive allosteric modulators (PAMs) 13. Despite the discovery of a 
variety of structurally distinct M1 mAChR-selective PAMs 7 some of these molecules 
have similarly run into issues regarding adverse responses that include temporal 
lobe seizures 7,14,15. These studies highlight the serious lack of appreciation of the 
subtle pharmacological and structural properties of both M1-selective PAMs and 
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orthosteric/bitopic ligands that underlie clinically efficacious responses versus 
adverse outcomes 10,15,16.  
Furthermore, the potential of utilising the concept of biased signalling 17 to avert 
muscarinic adverse responses that have thwarted drug discovery has similarly 
lacked thorough investigation 18.  In order to realise the full potential of M1 mAChR 
biased ligands, it will be necessary to dissect the in vivo signalling pathways that 
mediate clinically relevant M1 mAChR neurological processes, and distinguish these 
from pathways leading to adverse responses 17. We address this challenge here by 
generating a G protein-biased M1 mAChR by removing receptor phosphorylation 
sites and thereby uncoupling the receptor from phosphorylation/arrestin-dependent 
signalling. By knock-in of this G protein-biased receptor (M1-PD) into the gene locus 
of the wild type M1 mAChR, we were able to assign neurological and peripheral 
responses to either G protein-dependent or receptor phosphorylation/arrestin-
dependent signalling.  
We combined this approach with a unique application of Designer Receptor 
Exclusively Activated by Designer Drug (DREADD) technology, where the 
introduction of mutations in transmembrane domains 3 and 5 of the M1 mAChR 
generated a receptor mutant (M1-DREADD) that was unresponsive to the natural 
ligand acetylcholine, but rather was activated by the otherwise inert chemical ligand 
clozapine-N oxide (CNO)19. Whereas many other studies have used muscarinic 
DREADDs to investigate the role of G protein signalling in neuronal processes 20, 
here by knock-in of the M1-DREADD coding sequence into the M1 mAChR gene 
locus we express the M1-DREADD in place of the wild type M1 mAChR in a study 
designed to define the role and “druggablilty” of the M1 mAChR.  We predicted that 
the phenotype of this mutant mouse would mimic that of the M1-receptor knockout 
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(M1-KO) mice since the M1-DREADD receptor does not respond to acetylcholine. 
However, unlike M1-KO mice, deficits resulting from a loss of M1 mAChR activity 
would be corrected in the M1-DREADD mice by treatment with CNO. In this way we 
reasoned we could define physiological responses that might be targetable by 
pharmacological activation of the M1 mAChR. Using this approach together with the 
M1-PD mice and a mouse line expressing a phosphorylation-deficient version of the 
M1-DREADD (M1-DREADD PD) we describe here that pharmacological targeting of 
the M1 mAChR not only impacts on learning and memory but can also correct 
disturbances in anxiety-related behaviours and hyperactivity, suggesting that M1 
mAChR ligands hold the promise of treatment of a broad spectrum of symptoms 
associated with AD. By mapping the bimodal signalling pathways underlying 
neurological and adverse responses of the M1 mAChR we further conclude that 
ligands biased towards M1 mAChR phosphorylation/arrestin-dependent signalling 
will have efficacy in clinically-relevant responses, while minimising adverse effects 
including “epileptic-like” seizures. 
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Results  
Generation of the M1-DREADD mice 
Consistent with previous studies19, the human wild type M1 mAChR expressed in 
Chinese hamster ovary (CHO) cells was potently activated by acetylcholine while 
showing a weak response to CNO, in an inositol phosphate accumulation assay 
(Supplementary Table 1). CHO cells expressing the M1-DREADD receptor showed 
a significant (5000-fold) reduction in the potency of acetylcholine while responding to 
CNO with nM potency (Supplementary Table 1). Targeting the M1 mAChR gene 
locus with a construct that, following homologous recombination, replaced the coding 
sequence of the M1 mAChR with the coding sequence of the M1-DREADD (Figure 
1A and Supplementary Figure 1 A-C) resulted in mice that transcribed the M1-
DREADD mRNA in the hippocampus and cortex at levels that were not significantly 
different from that of the M1 mAChR in wild type animals (which refers to animals 
that express a wild type M1 mAChR tagged at the C-terminus with an HA-epitope 
tag) (Figure 1B). Furthermore, the M1-DREADD protein was expressed at 
comparable levels to that of the wild type receptor in the cortex of control mice, but 
slightly higher levels in the hippocampus (Figure 1C-D, Supplementary Figure 2). 
The M1-DREADD mice showed normal levels of breeding and indicators of good 
health.  
To establish the sensitivity of the M1-DREADD expressed in the engineered mice to 
muscarinic ligands, coupling of the M1-DREADD to heterotrimeric G proteins was 
assessed in membranes prepared from the cortex. In these experiments, CNO 
showed no significant activity in cortical membranes prepared from wild type 
animals, while the muscarinic agonist carbachol produced a robust increase in 
[35S]GTPgS binding (Figure 1E, Supplementary Table 2). In contrast, CNO 
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produced a potent increase in Gq/11-coupling in cortical membranes prepared from 
M1-DREADD mice while carbachol failed to stimulate a response (Figure 1F, 
Supplementary Table 2).  
Hence, the M1-DREADD in our engineered mice was expressed near equivalently to 
that of the M1 mAChR in wild type mice and was not activated by the natural ligand 
acetylcholine, but was instead activated by CNO.    
 
CNO reduces hyper-anxiety levels in M1-DREADD mice  
M1-KO animals showed an increased anxiety-like phenotype in an elevated plus 
maze (EPM) test as demonstrated by significantly fewer entries into the open arms 
of the maze compared to controls (Figure 2A-G). M1-DREADD mice similarly 
showed fewer entries into the open arms of the maze (relative to total entries) 
compared to controls, indicating that the M1-DREADD animals mimicked the 
phenotype of the M1-KO mice (Figure 2A-G). The hyper-anxiety phenotype shown 
by the M1-DREADD mice was restored to normal levels by the administration of 
CNO (0.3 mg/kg) 30 min prior to the behavioural test (Figure 2 A-G). Previous 
pharmacokinetic studies from our laboratory determined that 0.3 mg/kg CNO 
administration (i.p.) gave a plasma exposure of approximately 50 nM 21, a 
concentration sufficient to fully activate virally expressed muscarinic DREADDs in 
vivo. Importantly, CNO (0.3 mg/kg; i.p.) had no effects on the wild type mice nor the 
M1-KO mice in the EPM (Figure 2 A-G). These data indicate that loss of M1-AChR 
function results in an anxiety-like phenotype that is restored by direct activation of 
M1 mAChRs through selective ligands.  
 
 
 9 
Hyperactivity of M1 DREADD mice is restored by CNO 
Consistent with previous studies 22 we confirm that M1-KO mice are hyperactive in 
an open field test. (Figure 2H-K (also see; Figure 4E and G-K below)). Since M1-
DREADD is not responsive to the natural ligand, acetylcholine, mice expressing the 
M1-DREADD similarly displayed a hyper-locomotion phenotype (Figure 2H-K). The 
hyper-locomotion associated with both M1-KO and M1-DREADD animals was also 
evident when the mice were tested in a Y maze paradigm (Figure 2L and 
Supplementary Figure 3). Importantly, administration of CNO (0.3mg/kg) had no 
significant effects on the locomotion of wild type or M1-KO mice, but reduced the 
hyper-locomotion observed in M1-DREADD animals to levels similar to that seen in 
vehicle-treated control animals (Figure 2G and L and Supplementary Figure 3). 
These data indicate that not only are M1 mAChRs involved in regulating locomotion, 
but that modulation of locomotion is “druggable” via selective agonism of this 
receptor subtype. 
 
Generation of a phosphorylation-deficient M1 mAChR mouse 
Like many other GPCRs, muscarinic receptors operate through two signalling arms 
namely, via heterotrimeric G proteins and receptor phosphorylation regulated 
pathways23. The latter includes receptor coupling to arrestin-adaptor proteins and 
activation of arrestin-dependent processes such as receptor internalisation24. A 
mutant M1 mAChR that lacked all of the mass spectrometry identified 
phosphorylation sites25 and other potential sites in the third intracellular loop and C-
terminal tail (20 serine–alanine substitutions in total) (Figure 3A), was generated 
and expressed in HEK-293 cells. This mutant receptor showed robust coupling to 
Gq/11/calcium mobilisation (Figure 3B, Supplementary Table 3) while showing 
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reduced agonist-mediated receptor recruitment of arrestin (Figure 3C, 
Supplementary Table 3) and a deficit in receptor internalisation (Figure 3D, 
Supplementary Figure 4). These results are consistent with the notion that the 
phosphorylation-deficient receptor is “G protein-biased”.  
A receptor knock-in mouse that expressed the phosphorylation-deficient form of the 
mouse M1 mAChR was generated, termed M1-PD (Supplementary Figure 5). By 
comparing this mouse line with wild type controls (that express a C-terminally tagged 
wild type M1 mAChR) and M1-KO animals, it was our aim to differentiate between 
physiological responses that lie downstream of receptor phosphorylation-dependent 
signalling and those mediated by G protein activation. Radioligand binding assays 
determined that muscarinic receptor expression in M1-PD mice in the cortex was 
equivalent to that in wild type mice (Figure 3E). Transcription of the mutant receptor 
in the cortex and hippocampus of M1-PD mice was not significantly different from 
that of the M1 mAChR in control animals (Figure 3F) and quantification of Western 
blotting results revealed no significant difference in the expression levels of the 
mutant M1 mAChR in the hippocampus and cortex of M1-PD mice (Figure 3G-H 
and Supplementary Figure 6). Finally, the coupling to heterotrimeric G proteins (as 
determined in [35S]GTPγS assays and inositol 1,4,5-trisphosphate mass assays) of 
the M1 mAChR and phosphorylation-deficient variant was equivalent in cortical 
tissue extracts (Figure 3I-J, Supplementary Table 3).   
 
Neuro-physiology regulated by M1 mAChR phosphorylation 
We first tested the anxiolytic response in the M1-PD mice and found that, similar to 
the M1-KO mice, the M1-PD mice showed fewer entries into the open arms of an 
EPM (Figure 4A-E). This indicates that anxiolytic responses revealed in the studies 
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above are mediated by receptor phosphorylation-dependent signalling. Similarly, in a 
Y-maze spontaneous alternation paradigm testing spatial working memory, the M1-
PD mice showed significant deficit indicating that like the M1 mAChR-mediated 
anxiolytic response, this behaviour is also under the positive regulation of receptor 
phosphorylation (Figure 4F).   
Locomotion was initially assessed in the open field test where M1-PD mice did not 
mimic the hyperactivity phenotype of M1-KO mice (Figure 4G-J). Rather in this test 
(Figure 4J) and in the EPM (Figure 4E) the total distance travelled by the M1-PD 
mice was less than wild type indicating that these mice were hypo-active. 
Interestingly, although locomotion monitored over a 24 hour period using telemetry 
showed the M1-KO mice to be hyper-active, consistent with the above data, under 
this paradigm the M1-PD showed activity equivalent to wild type mice (Figure 4K). 
The conclusion from these locomotion studies was that, in contrast to the anxiolytic 
and spatial working memory responses, regulation of locomotor behaviour is not 
dependent on receptor phosphorylation, but appears to be regulated in a G protein-
dependent manner. The hypo-locomotion response observed in some of the tests 
(EPM and Y maze) might indicate that although mediated by G protein pathways, M1 
mAChR locomotion might be desensitised by receptor phosphorylation resulting in 
hypo-locomotion when phosphorylation sites are removed (see; Figure 4E and J). 
We next compared these central responses with M1-mAChR mediated 
salivary secretion. M1-KO mice showed reduced salivary secretion in response to 
the muscarinic receptor agonist pilocarpine, as previously described26, but this was 
not mimicked by the M1-PD mice (Figure 4L) indicating that this response also is 
downstream of G protein-dependent signalling (summarised in Figure 4M). 
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M1 mAChR phosphorylation reduces adverse responses 
To further probe the role of receptor phosphorylation-dependent signalling in M1 
mAChR-mediated responses, an M1-DREADD receptor was generated where the 
phosphorylation sites had been removed (Figure 5A). In in vitro inositol phosphate 
assays, this phosphorylation-deficient DREADD receptor was activated by CNO with 
similar potency and efficacy to the fully phosphorylatable version of M1-DREADD 
(Supplementary Figure 7A, Supplementaty Table 1). Consistent with a role for 
receptor phosphorylation in driving phosphorylation/arrestin-dependent processes, 
the phosphorylation deficient M1-DREADD was defective in agonist (CNO) mediated 
receptor internalisation (Supplementary Figure 7B-C).  
A knock-in mouse expressing the phosphorylation-deficient M1-DREADD in place of 
the M1 mAChR was generated and termed M1-DREADD PD (Supplementary 
Figure 8A-B). The M1-DREADD PD mutant was transcribed at levels equivalent to 
that of the M1-DREADD receptor in M1-DREADD mice and the M1 mAChR in wild 
type mice (Figure 5B).  
Possibly due to the fact that the M1-DREADD receptor is not activated by 
endogenous acetylcholine, the levels of expression of this receptor in hippocampus 
(but not the cortex) of engineered mice were slightly higher than that of the wild type 
receptor (Supplementary Figure 2). The expression of M1-DREADD PD was also 
significantly higher than wild type receptor (Figure 5C-D and Supplementary 
Figure 2). Importantly, there were no statistically significant differences between the 
expression levels of M1-DREADD and M1-DREADD PD receptors in the 
hippocampus or cortex (Supplementary Figure 2). This is relevant since the M1-
DREADD acts as the control for the M1-DREADD PD (we do not use wild type mice 
as controls when looking at the phenotype of the M1-DREADD PD).  
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G protein coupling assays in cortical membranes derived from M1-DREADD and M1-
DREADD PD showed that CNO stimulated robust increases in Gq/11 coupling in both 
variants whereas carbachol gave no significant increases (Figure 5E-F, 
Supplementary Table 2). When normalised to expression levels we estimated that 
M1-DREADD PD signalling to Gq was ~1.5 fold higher than M1-DREADD.   
 
CNO induces adverse responses in M1-DREADD PD mice 
The aim here was to investigate if physiological responses mediated by CNO 
administration to animals expressing the M1-DREADD receptor were similarly 
responsive in M1-DREADD PD mice. In this way we might further predict the impact 
of biased M1 mAChR selective ligands. However, administration of CNO to M1-
DREADD PD mice resulted in profound adverse responses (Supplementary Table 
4) including both central and peripheral responses such as gastro-intestinal 
disturbances and salivary hyper-secretion. These adverse responses have 
previously been associated with the failure of muscarinic drug discovery 
programmes9,12,14,27-30. Most striking however was the severe seizures characteristic 
of cholinergic temporal lobe “epileptic-like” seizures 31-33. We further characterised 
these seizures using surface EEG recordings to monitor cortical activity (Figure 5G-
H). CNO induced a reduction in EEG power following CNO administration, followed 
by sporadic seizure activity, which subsequently developed into full epileptic-like 
episodes around 25-35 min after CNO administration. Importantly, the same dose of 
CNO (0.3 mg/kg) administered to M1-DREADD mice had no adverse effects 
(Supplementary Table 4). 
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G protein biased systems show enhanced adverse responses 
These data led to the prediction that a muscarinic-receptor ligand biased toward G 
protein-dependent signalling versus receptor phosphorylation-dependent signalling 
will show more adverse responses than a non-biased ligand. To test this prediction 
we profiled the G protein/receptor phosphorylation bias of two well-characterised 
muscarinic ligands, pilocarpine 31 and GSK1034702 10-12. Both these ligands 
stimulated Gq/11-dependent signalling to inositol phosphate accumulation and 
phosphorylation and activation of extracellular signal-regulated kinase 1/2 (pERK1/2) 
(Figure 6A-B). Similarly both pilocarpine and GSK1034702 stimulated 
phosphorylation of serine 228 in the third intracellular loop of the M1 mAChR, a site 
previously showed to be highly sensitive to agonist-mediated phosphorylation 25 
(Supplementary Table 5; Figure 6C). Fitting the concentration response curves to 
the operational model of agonism we derived a transduction co-efficient (t tau) for 
each of the responses. By comparing these with the transduction co-efficient of the 
natural ligand acetylcholine we calculated bias of the two ligands between G protein 
coupling and receptor phosphorylation which was expressed as a bias-factor 
(Supplementary Table 6, Figure 6D). This analysis determined that pilocarpine 
showed bias toward G protein signalling, whereas GSK1034702 showed no bias 
between G protein coupling and receptor phosphorylation pathways 
(Supplementary Table 6, Figure 6D).  
That these ligands show similar properties in vivo was investigated by administration 
of either pilocarpine (30 mg/kg) or GSK1034702 (10 mg/kg) at doses that resulted in 
equivalent levels of receptor occupancy (60%) in rats, as determined using an M1 
mAChR PET tracer, LSN3172176 34 (Supplementary Figure 9). At this dose 
pilocarpine resulted in a robust inositol phosphate response that was ~2 fold greater 
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than that observed for GSK1034702 (Figure 6E-F), supporting the conclusion that 
pilocarpine is more efficacious in stimulating G protein-dependent signalling 
compared to GSK1034702 in brain tissue. 
We then examined adverse events in response  to these two ligands in wild type and 
M1-PD mice using doses that gave equivalent receptor occupancy. Consistent with 
the notion that ligands biased towards G protein signalling would show more 
pronounced adverse responses, we observed that pilocarpine induced significant 
central (tremors, grasping and convulsions) and peripheral adverse responses 
(piloerection, lacrimation and diarrhoea) in both WT and M1-PD mice 
(Supplementary Table 7). Interestingly, salivation was the only response that was 
lower in the M1-PD compared to WT in response to pilocarpine (Supplementary 
Table 7). Whereas this might point to salivation being downstream of receptor 
phosphorylation dependent signalling, the data in Fig 5L would point to this response 
being solely G protein mediated.   In contrast to pilocarpine, GSK1034702, which 
showed no stimulus bias, also showed no adverse responses in WT mice. It is only 
in the M1-PD mice (i.e. in a mouse background where the receptor is G protein-
biased) where adverse central and peripheral responses were observed with this 
ligand (Supplementary Table 8).  
We next took advantage of an earlier finding from our laboratory that the bitopic 
nature of GSK1034702 binding to M1 mAChR meant that GSK1034702 acted as an 
agonist at both wild type M1 mAChR and M1-DREADD receptors (see; 10). This 
meant that this ligand could uniquely be used as an agonist in wild type mice, as well 
as M1-DREADD and M1-DREADD PD mice. Administration of GSK1034702 at a 
dose that had no adverse effects in M1-DREADD mice (30 mg/kg) had profound 
peripheral and central adverse effects in M1-DREADD PD mice (Supplementary 
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Table 9), a result consistent with the notion that M1 mAChR signal transduction that 
is biased toward G protein coupling results in adverse central and peripheral 
cholinergic responses.  
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Discussion  
In this study we generated a series of novel chemogenetic and G protein-bias mouse 
models that not only revealed the importance of phosphorylation/arrestin dependent 
signalling in M1 mAChR-mediated learning and memory and anxiolytic behaviours 
but also established that the phosphorylation status of the M1 mAChR significantly 
contributes to minimising cholinergic adverse effects. These adverse effects, both 
peripheral SLUDGE effects (salivation, lacrimation, urination, defecation, gastro-
intestinal disturbance and emesis) and central adverse responses, such as seizures, 
have represented one of the major barriers to the success of targeting muscarinic 
receptors in AD30,35. Furthermore, our data suggest that in addition to pro-cognitive 
benefits, targeting the M1 mAChR in AD might also have an impact on associated 
behavioural abnormalities including anxiety and hyper-activity.  
By uniquely employing DREADD-knockin mice we not only mimic the 
pharmacological activation of M1 mAChRs but also reveal something of the nature of 
acetylcholine neuro-signalling since it would appear that cholingeric tone, disrupted 
in AD, can be mimicked by pharmacological agents allowing for “normal” neuronal 
activity and behavioural responses in a background where cholinergic transmission 
has been compromised. 
In this study we wanted to determine the potential of employing the concept of 
biased ligands in directing M1 mAChR signalling to therapeutically beneficial 
pathways by mapping those responses that lie downstream of G protein-dependent 
versus phosphorylation/arrestin pathways (summarised in Fig 4M). To do this we 
generated a G protein biased M1 mAChR by deleting all the potential phospho-
acceptor sites. Interestingly, removal of these phosphorylation sites reduced, but did 
not eliminate, the interaction of the receptor with arrestin. This is in contrast to other 
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GPCR subtypes where removal of phosphorylation sites results in almost complete 
absence of receptor/arrestin interaction (e.g. ref36). GPCRs can interact with 
arrestins via both a phosphorylation-dependent interaction with the phospho-sensor 
and via interaction with the activation sensor37.  Structural studies are revealing the 
molecular basis for this bimodal binding38,39, in particular the role of differential 
phosphorylation patterns driving different arrestin conformations and signalling 
outputs40,41 - supporting the hypothesis of a phosphorylation barcode 42,43. Here we 
report that the interaction of the M1 mAChR with arrestin, similar to that previously 
reported for the M3 mAChR 23,44,45, is only partially dependent on the 
phosphorylation status of the receptor indicating that the activation sensor on 
arrestin plays an equally important role as the phosphorylation sensor for the 
interaction of the M1 mAChR with arrestin. This may be significant when interpreting 
the phenotypic data of the M1-PD mice since the phenotypes identified here as 
dependent on the phosphorylation status of the M1 mAChR might not necessarily be 
due to a deficiency in receptor/arrestin interaction. Rather it is possible that receptor-
phosphorylation is important for the correct assembly/activity of M1 mAChR 
signalling complexes in neurons in a manner that is independent of arrestin. 
Classically, phosphorylation of GPCRs is related to receptor desensitisation 46,47. 
Hence, one explanation for the phenotypes observed in the M1-PD mice might be 
that the receptor is unable to undergo phosphorylation-dependent desensitisation. 
That this might be the case was illustrated by the examination of the locomotion 
response. In agreement with previous studies 22,48, we demonstrate that M1-KO mice 
are hyper-active, indicating a role for the M1 mAChR in reducing locomotion. 
However, M1-PD mice are hypo-active, a result that might be interpreted to mean 
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that the phosphorylation-deficient receptor itself is over-active due possibly to a lack 
of desensitisation.  
However, when we assess the coupling of the phosphorylation-deficient receptor to 
G protein signalling in membranes and cortical slices from tissues derived from M1-
PD mice we see only a very small increase in coupling to G protein signalling. 
Furthermore, salivary secretion, which we show here is downstream of G protein 
coupling is not significantly affected in the M1-PD mice. These data point to the 
intriguing possibility that some physiological responses mediated by G protein 
signalling are desensitised by receptor phosphorylation  (e.g. locomotion) whilst 
others (e.g. salivary secretion) are not.  
The impact of biased signalling on cholinergic adverse responses was strikingly 
revealed in a set of experiments employing a G protein-biased M1-DREADD mutant 
mouse. In this mouse line we found that administration of CNO, at concentrations 
that caused no adverse responses in wild type or M1-DREADD mice, resulted in 
profound peripheral and central adverse responses, including seizures. Whereas it is 
clear from previous studies that adverse responses might be related to the degree of 
efficacy of muscarinic ligands (including the extent of co-operativity and intrinsic 
activity of PAMs) 7,15 there has not been any previous indication that receptor 
phosphorylation-dependent processes might have a role in regulating adverse 
responses. Given our data it might be anticipated that ligands showing signalling 
bias away from receptor phosphorylation pathways and towards G protein coupling 
might show more pronounced cholinergic adverse responses. This was found to be 
the case with pilocarpine, which we show here to be both G protein biased and 
possessing pronounced seizurogenic activity (consistent with previous studies31-33). 
In contrast, GSK1034702, which was not biased, showed no seizures when 
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administered to WT mice at a dose that gave the same receptor occupancy as 
pilocarpine. Interestingly, GSK1034702 only induced cholinergic adverse responses 
in phosphorylation-deficient, G protein-biased, mice (i.e. M1-PD and M1-DREADD 
PD). These data point to muscarinic ligands with a bias toward receptor 
phosphorylation-dependent signalling as having a lower propensity to mediating 
adverse responses.  
Our study adds to a growing body of evidence that M1 mAChRs can be responsible 
for peripheral adverse effects previously thought to be mediated by M2/M3 
receptors27,29,49. Hence, simply developing highly selective M1 mAChR agonists 
might not be sufficient to avert cholinergic side effects. This conclusion is supported 
by reports that selective M1 mAChR PAMs also display adverse cholinergic 
responses7,14,15. These adverse events appear to be linked with intrinsic activity 
since those PAMs possessing high agonist activity also show cholinergic adverse 
responses7,14,15 whilst those PAMs devoid of intrinsic agonist activity induce no 
cholinergic toxicity 7,50. What is not clear, and a point that certainly deserves further 
investigation, is whether PAMs that possess high agonist activity and significant 
adverse responses are also biased toward G protein signalling. That this may be the 
case is supported by data where those PAMs inducing adverse responses (e.g. PF-
06767832 and PF-06827443) also stimulate robust inositol phosphate signalling 
(indicative of Gq-signalling) in striatal tissue 14,29.  
Given these studies, and taking into consideration our findings, we conclude that to 
minimise cholinergic side effects whilst delivering maximal clinical efficacy across a 
range of AD symptoms next generation M1 mAChR ligands should, in addition to 
being highly selective and have carefully calibrated efficacy, also drive receptor 
phosphorylation-dependent signalling. 
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Figure Legends 
Figure 1: Generation of the M1-DREADD knock-in mouse 
(A) Snake-plot of the M1 receptor identifying the mutations introduced to generate 
the M1-DREADD receptor. (B) Quantitative RT-PCR showing the transcription of M1 
mAChR RNA in the hippocampus or cortex of wild type (WT) or M1-DREADD mice. 
Data are expressed as a ratio of β-actin RNA transcription (n=3 mice). (C, D) 
Solubilised membranes prepared from the hippocampus (C) or cortex (D) of WT, M1-
HA, M1-DREADD and M1-KO mice were probed in Western blot analysis for the 
expression of M1 mAChR using an antibody for the HA tag.  Data shown are two 
separate mice for each genotype, with similar data being obtained on at least two 
further occasions (see; figS2). Na+/K+ATPase expression was used as a loading 
control. (E, F) Stimulation of [35S]-GTPγS binding to cortical membranes prepared 
from WT, M1-HA (E) or M1-DREADD (F) mice following stimulation with carbachol 
(CCh) or clozapine-n-oxide (CNO). Data are expressed as means ± S.E.M. of 3-4 
independent experiments performed in duplicate and normalized to the maximal 
response at the WT receptor.   
 
Figure 2: Altered phenotypes of M1-DREADD mice are corrected by CNO 
(A-F) Heat maps showing the occupancy of wild type (WT) (A, D), M1-KO (B, E) and 
M1-DREADD (C, F) mice in the elevated plus maze (EPM) test following 
administration of vehicle (A-C) or 0.3 mg/kg CNO (D-F) (i.p. 30 min prior to test). 
Heat maps represent the occupancy (Blue = 0 sec occupancy, red = 5 sec 
occupancy) of 2-6 mice per treatment group. (G) Mean anxiety level of WT, M1-KO 
or M1-DREADD mice treated with vehicle or CNO (calculated as a ratio of 
open/closed arm entries divided by the total number of entries) prior to the EPM test. 
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Data represent 16-26 individual mice, and were analysed using a two-way ANOVA 
with a Sidak’s multiple comparison test (*P<0.05, **P<0.01, ***P<0.001).   
(H-J) Representative motion plots of wild type (WT) (H), M1-KO (I) or M1-DREADD 
(J) mice in the open field test. (K) Average distance travelled by WT, M1-KO or M1-
DREADD mice over a 10 min period in the open field test (inset total distance for 
each genotype over a 10 min period). Data are means of 3-5 separate mice. (L) 
Total distance travelled in an 8 min period by WT, M1-KO or M1-DREADD following 
administration of vehicle or 0.3 mg/kg CNO 30 min prior to a Y maze test. Data are 
means ± S.E.M. of 4-13 individual mice, and were analysed using a two-way ANOVA 
with a Sidak’s multiple comparison test (**P<0.01; ***P<0.001).   
 
Figure 3: Generation of the G protein biased M1-PD knock-in mouse  
(A) Snake-plot of the M1 receptor identifying the mutations introduced to generate 
the M1-PD receptor.  (B) Stimulation of intracellular Ca2+ release in HEK cells 
transiently transfected with mouse M1-WT or M1-PD mAChRs. (C) β-arrestin 
recruitment to the M1 mAChR determined using PathHunter HEK cells expressing 
either the M1 WT or M1-PD receptor. Shown are concentration response curves to 
the full muscarinic receptor agonist oxotremorine-M (oxo-M). The data are the 
means ± S.E.M. of three independent experiments and are expressed as a 
percentage of the maximal response to Oxo-M at the wild type (WT) M1 mAChR. (D) 
Representative images showing the localisation of HA-tagged M1 WT or M1-PD in 
CHO cells stimulated with vehicle or 100 μM carbachol for 1 hour prior to fixation 
with 4% PFA (63x objective). Data shown are representative of 4 individual 
experiments. (E) [3H]-NMS binding to cortical membranes prepared from WT M1-HA 
or M1-PD mice (n=4). Data shown are the means ± S.E.M. (F) Quantitative RT-PCR 
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showing the transcription of M1 mAChR RNA in the hippocampus or cortex of WT 
and M1-PD mice. Data are expressed as a ratio of β-actin RNA transcription (n=3 
mice). (G, H) Solubilised membranes prepared from the hippocampus (G) or cortex 
(H) of WT M1-HA, M1-PD and M1-KO mice were probed in Western blot analysis for 
the expression of M1 mAChR using an antibody for the HA tag.  Data shown are two 
separate mice for each genotype, with similar data being obtained on at least two 
further occasions (see; fig S6). Na+K+ATPase expression was used as a loading 
control. (I, J) Stimulation of [35S]-GTPγS Gq/11 binding (I) or Ins(1,4,5)P3 
accumulation (J) in cortical tissue prepared from WT M1-HA or M1-PD mice 
following stimulation with CCh. Data are expressed as means ± S.E.M. of 3 
independent experiments performed in duplicate ([35S]-GTPγS) or triplicate 
(Ins(1,4,5)P3 accumulation) and normalized to the maximal response at the WT 
receptor.   
 
Figure 4: Mapping of bimodal signalling to M1 mAChR physiological 
responses  
(A-C) Heat maps showing the occupancy of wild type (WT) (n=13), M1-PD (n=14) or 
M1-KO (n=4) mice in the open- or closed arms of the EPM (blue = 0 sec occupancy, 
red = 5 sec occupancy). (D) Anxiety level of WT (n=21), M1-KO (n=15) or M1=PD 
(n=14) mice (calculated as a ratio of open/closed arm entries divided by the total 
number of entries).  (E) Total distance travelled in the EPM of WT (n=13), M1 PD 
(n=14) or M1-KO (n=15). Data shown are means ± S.E.M. and were analysed using 
a one-way ANOVA with Dunnett’s multiple comparisons test; *P<0.05; ***P<0.001. 
(F) WT or M1-PD mice were tested for 8 min in a Y maze spontaneous alternation 
paradigm to assess spatial working memory. Data shown are means ± S.E.M. and 
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were analysed using a Student’s t test (*P<0.05). (G-I) Representative track plots of 
WT, M1-DREADD and M1-KO mice in the open field (OF) test. (J) Total distance 
travelled in a 10 min period by WT, M1-PD and M1-KO mice during an OF test. Data 
shown are means ± S.E.M. and were analysed using a one-way ANOVA with 
Dunnett’s multiple comparisons test; *P<0.05. (K) Basal locomotor activity of WT 
M1-HA, M1-PD and M1-KO mice was assessed using in vivo telemetry recordings. 
Mean locomotor activity ± S.E.M. of 8 mice over a 24 hour period is shown, with total 
locomotor activity during this period calculated by measurement of the area under 
the curve (AUC). (L) Salivary secretion in response to pilocarpine (1 mg/kg) 
administration was measured in WT, M1-PD and M1-KO mice. The data represent 
the means ± S.E.M. of n=5-7 mice. Data were analysed using a one-way ANOVA 
with Dunnett’s multiple comparisons test compared to WT mice; *P<0.05. (M) An 
illustration of the M1 mAChR physiological responses lying downstream of G protein-
dependent signalling (saliva secretion and locomotion) versus phosphorylation-
dependent signalling (anxiolytic behaviour and spatial working memory). 
 
Figure 5: M1-DREADD PD mice show epileptic-like seizures 
(A) Snake-plot of the M1 mAChR identifying the mutations introduced to generate 
the M1-DREADD PD receptor. (B) Quantitative RT-PCR showing the transcription of 
M1 mAChR RNA in the hippocampus or cortex of wild type (WT), M1-DREADD or 
M1-DREADD PD mice. Data are expressed as a ratio of β-actin RNA transcription 
(n=3 mice). (C, D) Solubilised membranes prepared from the hippocampus (C) or 
cortex (D) of WT M1-HA, M1-DREADD, M1-DREADD PD and M1-KO mice were 
probed in Western blot analysis for the expression of M1 mAChR using an antibody 
for the HA tag.  Data shown are two separate mice for each genotype, with similar 
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data being obtained on at least two further occasions (see; fig S2). Na+K+ATPase 
expression was used as a loading control. (E-F) Stimulation of [35S]-GTPγS binding 
to cortical membranes prepared from M1-DREADD (E) or M1-DREADD PD (F) mice 
following stimulation with CCh or CNO. Data are expressed as means ± S.E.M. of 3-
4 independent experiments performed in duplicate and normalized to the maximal 
response at the WT receptor. (G) Raw cortical EEG signals (top) and the 
spectrogram (bottom) in a representative M1-DREADD PD mouse following 
administration of CNO (0.3 mg/kg; i.p.) after 15 min of recording basal cortical 
activity. (H) Normalized EEG power in M1-DREADD or M1-DREADD PD mice 
treated with vehicle (5% glucose) or CNO (0.3 mg/kg). Data shown are means ± 
S.E.M. of 4-8 individual mice and were analysed using a repeated measures 
ANOVA, F(3, 3119) = 5.53, p = 0.029. 
 
Figure 6: Pilocarpine shows G protein bias, whilst GSK1034702 is not biased 
Inositol phosphate (IP1) accumulation (A), ERK1/2 phosphorylation (pERK) (B) or 
M1 mAChR phosphorylation at Serine 228 (pSer228) (C) stimulated by acetylcholine 
(ACh), pilocarpine or GSK1034702 in CHO cells stably expressing the mouse wild 
type M1 mAChR. Dashed line shows data generated as part of a previous dataset 
for comparison (see; ref 10). (D) Preferential signalling bias ((ΔΔLog10(τ/KA)) 
stimulated by ACh, pilocarpine and GSK1034702 towards IP1, pERK or pSer228 
pathways at the WT M1 receptor is shown. Data are means ± S.E.M. and used ACh 
as the reference ligand. (E, F) Stimulation of inositol phosphate accumulation in the 
frontal cortex of male Sprague Dawley rats followed by administration of increasing 
concentrations of GSK1034702 (E) or pilocarpine (F). Data shown are means ± 
S.E.M. of 3-4 rats and were analysed using a two-way ANOVA with Dunnett’s 
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multiple comparison, where *P<0.05, **P<0.01 versus vehicle, and #P<0.05, 
##P<0.01 versus LiCl. 
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Online Materials  
Animal maintenance 
All mice were bred as homozygous onto a C57BL/6J background. Male and female 
animals at 8–12 weeks old were used if not stated otherwise. Mice were fed ad 
libitum with a standard mouse chow and were maintained within the animal facility at 
least 1 week prior to experiments. Animals were cared for in accordance with 
national guidelines on animal experimentation. All experiments were performed 
under a project license from the British Home Office (United Kingdom) under the 
Animals (Scientific Procedures) Act of 1986.  
 
Generation of M1-PD, M1-DREADD, M1-DREADD PD knock-in animals 
For the generation of the knock-in animals a construct containing the loxP-Stop-loxP 
cassette upstream of a sequence encoding for the M1-HA, M1-PD, M1-DREADD or 
M1-DREADD PD was generated and inserted within the encoding exon (exon 3) of 
the M1 mAChR gene (Chmr1). All constructs were tagged with a HA epitope 
sequence (YPYDVPDYA) appended to the C terminus. The M1-DREADD is the 
coding sequence for the humanized (humanizing mutations V5A, S254T, K320R, 
G337A, and V413I) M1 mAChR with two mutations Y106C and A196C (see; Fig 
1A). The M1-PD is the coding sequence of the mouse M1 mAChR with mutations in 
the third intracellular loop and C-terminal tail that replace 20 serine resides with 
alanine (see; Fig 4A). The M1-DREADD PD is the coding sequence for the 
humanized M1-DREADD plus 20 serine-alanine mutations in the third intracellular 
loop and C-terminal tail (see; Fig 6A).  
The targeting vectors containing the coding sequences for the muscarinic receptor 
mutants were subsequently transfected into embryonic stem (ES) cells derived 
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from C57BL/6J mice and neomycin-resistant ES cells were selected. Homologous 
recombination was validated by PCR and southern blot. Recombined ES cell clones 
were injected into blastocysts for the generation of chimeric mice. Breeding of 
chimeras with C57BL/6 and Cre-recombinase expressing mice allowed the 
generation of heterozygous mice. Heterozygous animals were bred for the 
generation of homozygous lines. M1-KO mice were conditional M1-PD mice 
expressing a Stop of transcription cassette flanked with loxP sites upstream of the 
M1-PD cDNA. To obtain these mice please contact the corresponding authors. The 
generation of M1-HA, M1-PD, M1-DREADD, M1-DREADD PD and M1-KO mice was 
carried out by genOway.   
Note that the M1-KO strain was generated using conditional M1-PD mice that were 
not crossed with any CRE-deleter strains therefore leaving the stop cassette 
upstream of the ATG intact resulting in a mouse strain where the receptor was not 
expressed (see; the summary of the construct Fig S4).  
 
qRT-PCR 
RNA was isolated from hippocampus or cortex of WT, M1-DREADD, M1-DREADD 
PD, M1-PD or M1-KO mice using Qiagen lipid tissue RNeasy kit as per manufacturer 
instructions. RNA concentration was quantified using a Nanodrop and 1 μg total 
RNA template per reaction was used for cDNA synthesis using SuperScript III first-
strand synthesis SuperMix (Invitrogen). RNA/water (total 8 μl), 2 μl RT enzyme and 
10 μl 2x RT reaction mix were mixed together and incubated for 10 min at 25°C, 
followed by 30 min at 50°C, followed by 5 min at 85°C. Samples were then chilled on 
ice. Each reaction was performed in the presence and absence of RT enzyme (- RT 
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control). Finally, cDNA was incubated with 1 μl (2U) of E. Coli RNAse H and at 37°C 
for 20 min and subsequently stored at -20°C until qRT-PCR was performed. 
For qRT-PCR, the following M1 mAChR primers were used (at 300:300 dilution): 
F: 5’ CAAGTGGCATTCATCGGGATCACC 
R: 5’ GAGAAAGTGCCAATGATGAGATCAGC 
Each reaction was performed in triplicate. Each reaction was performed in a total 
volume of 25 μl containing: 12.5 μl SYBR Green Master Mix, 0.75 μl F primer (10 μM 
stock), 0.75 μl R primer (10 μM stock), 10 μl water and 1 μl cDNA (or –RT sample).  
 
IP1 accumulation assay 
Human M1-WT or M1-DREADD PD constructs were stably expressed in CHO-FlpIn 
cells and grown to confluence in T75cm2 flasks in Ham’s F-12 media containing 10% 
fetal bovine serum and 1% penicillin/streptomycin and under hygromycin B selection 
(400 μg/ml). Cells were harvested and centrifuged at 1000 xg for 3 min prior to 
resuspension in 1X stimulation buffer ((in mM): HEPEs, 10; CaCl2, 1; MgCl2, 0.5; 
KCl, 4.2; NaCl, 146; glucose, 5.5; LiCl, 50; pH7.4) at 1.43 x 106 cells/ml. Test 
compounds (7 μl/well) and cell suspension (7 μl/well) were added to 384-well white 
proxiplates (PerkinElmer). Following a brief centrifugation, plates were incubated at 
37°C for 45 min. The IP1-d2 conjugate and the anti-IP1 cryptate Tb conjugate (IP1 
Tb™ assay kit, CisBio) were diluted 1:30 in lysis buffer and 3 μl of each were added 
to each well. The plate was incubated at 37°C for 1h and FRET between d2-
conjugated IP1 (emission at 665 nm) and Lumi4™-Tb cryptate conjugated anti-IP1 
antibody (emission at 620 nm) was detected using an Envision plate reader 
(PerkinElmer). Results were calculated from the 665/620 nm ratio and normalised to 
the maximum response stimulated by ACh. 
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ERK1/2 phosphorylation 
Stimulation of ERK1/2 phosphorylation (Thr 202/Tyr 204) was assessed using the 
CisBio Phospho-ERK Cellular Assay Kit. Confluent monolayers of CHO Flp-In cells 
stably expressing the human M1 mAChR were serum starved overnight prior to the 
experiment. Cells were washed with 100 μl phosphate-buffered saline and incubated 
in serum free F12 medium at 37°C. Cells were stimulated with test compounds for 5 
min at 37°C in a final volume of 200 μl. The stimulations were terminated by rapid 
aspiration and addition of 50 μl lysis buffer supplemented with blocking reagent. 
Lysates were gently agitated at room temperature for 30 min. Subsequently, 16 μl of 
this lysate was transferred to a 384-well white ProxiPlate (PerkinElmer) and 
incubated with 4 μl premixed antibody solution for 2 hours at room temperature. 
Fluorescence emission (665 and 620 nm) was determined using a PHERAstar plate 
reader (BMG Labtech).  
 
Cell culture and transfection (for Ca2+ and β-arrestin recruitment assays) 
PathHunter™ HEK293:b-arrestin:EA cells were transfected with the mouse WT or 
the mouse phosphorylation-deficient M1 mAChR in the ProLink vector (DiscoverX, 
UK), and grown under antibiotic selection (G418) to produce a stable pool of cells 
expressing the receptor. HEK293 wt/pdM1:b-arrestin:EA cells were maintained in 
DMEM medium containing L-glutamine supplemented with foetal bovine serum 
(FBS; 10 % v/v), hygromycin B (250 µg ml-1) geneticin G418 (500 ug ml-1) at 37°C, 
5% CO2.  
 
Intracellular Ca2+ measurement 
 36 
PathHunter™ HEK293 wt/pdM1:b-arrestin cells were seeded into 96-well clear 
bottom, black plates (Costar) at 40,000 cells/well in 90 µl cell culture medium and 
incubated at 37 °C, 5 % CO2 overnight to achieve a confluent monolayer. On the day 
of the experiment, 30 µL of 4x Ca2+ no-wash assay kit 4 (Molecular Devices) 
containing 0.02 % pluronic acid (1:1); 2.5 mM probenecid, was added to each well of 
the 96-well cell plate and incubate at 37°C, 5 % CO2 for 30 min. Agonist-induced 
changes in Ca2+i concentration were then monitored over time using a FlexStation 3 
(Molecular Devices, UK). Basal fluorescence was monitored for 16 s prior to addition 
of a range of M1 mACh receptor agonists, after which changes in fluorescence 
recorded for a further 60 sec. Responses to agonist were expressed as change in 
fluorescence from baseline to peak. The maximum fluorescence was taken as the 
highest point of the initial peak following agonist addition. The minimum fluorescence 
was taken as the background fluorescence prior to agonist addition.  
 
Arrestin recruitment assay  
PathHunter™ HEK293 wt/pdM1:b-arrestin cells cells were seeded overnight in white, 
clear bottom 384-well ViewPlates (PerkinElmer, UK) at 8,000 cells/well in 20 µl cell 
culture medium and incubated at 37°C, 5 % CO2 overnight to achieve a confluent 
monolayer. On the day of the assay, spent medium was removed and replaced with 
HBSS containing 0.1 % BSA (w/v) and 20 mM HEPES, at pH 7.4. Cells were 
stimulated with a range of M1 mACh receptor agonists for 2 hr (in 5 µL), after which 
time 25 µL or proprietary Flash detection reagent (DiscoveRx, UK) was added and 
plate incubated for 15 min at room temperature in the dark. Luminescence was read 
on the ClarioStar (BMG, UK) using the Luminescent protocol, no filter.  
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Western Blotting  
Preparation of membrane extracts 
Membrane extracts were prepared following a protocol similar to the membrane 
preparation described by1. Briefly, hippocampi were homogenised by sonication at 3-
5 µg amplitude in 25 mM sodium phosphate buffer, pH 7.4, and containing 
proteinase inhibitors. Samples are then centrifuged at 20,000 xg for 30 min at 4 °C. 
The pellets were then incubated with 1.2 % digitonin in 25 mM sodium phosphate 
and 5 mM MgCl2 buffer (pH 7.4) overnight at 4°C with end over end rotation. After 
centrifugation of samples at 20,000 xg for 30 min at 4°C, the supernatants 
(membrane extracts) were transferred to fresh microcentrifuge tubes and stored at -
80°C until use. Protein concentrations were determined by using the Micro BCA 
protein assay reagent kit according to the manufacturer’s instructions. 
 
Western blotting analysis 
Samples were incubated with Laemmli loading buffer containing 5% β-
mercaptoethanol for 30 min at 37°C and loaded in 7.5% SDS-Tris-glycine 
polyacrylamide gels. Samples were run at ±100 V following the transfer onto 
nitrocellulose membranes that were blocked for 2 h with 5% fat free milk in TBS-T 
(0.1% tween-20 in TBS at pH 7.4). Membranes were then incubated with the 
respective primary antibody overnight at 4°C, then washed three times with TBS-T 
(10 min each wash) and incubated with the respective secondary antibody (1:5000) 
conjugated to horseradish peroxidase. Proteins were visualised with the ECL 
detection system (signal westpico plus chemiluminsescent substrate #34578). 
 
[3H]-NMS binding 
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Membrane preparations of mouse hippocampus or cortex (50 μg/tube) were 
incubated in binding buffer (in mM: HEPEs, 50; NaCl, 110; KCl, 5.4; CaCl2, 1.8; 
MgSO4, 1; glucose, 25; sucrose, 58; pH 7.4) containing increasing concentrations 
(0.1 - 5 nM) of [3H]-N-methyl scopolamine ([3H]-NMS) for 1 hour at 37°C. Membrane-
bound ligand was separated from free ligand by rapid filtration onto GF/B glass 
microfiber filters followed by three washes with ice-cold 0.9% NaCl. Membrane 
bound radioactivity was determined by liquid scintillation (Perkin Elmer Ultima Gold) 
counting. Nonspecific binding was determined in the presence of atropine (1 μM) 
during the incubation with [3H]-NMS.  
 
[35S]-GTPyS assay 
M1-WT, M1-DREADD, M1-PD and M1-DREADD PD (8-12 weeks) were humanely 
killed and cortical tissue was dissected on ice. Tissue was suspended in ice-cold 
buffer A (containing 0.9% (w/v) NaCl, 10 mM HEPES, 0.2% (w/v) EDTA, pH 7.4) and 
homogenised (4 x 5 sec bursts) using a Polytron homogeniser. The suspension was 
centrifuged at 200 xg for 5 min at 4°C using an Eppendorf 5810R bench-top 
centrifuge. Supernatants were collected and re-homogenised as above. The 
suspension was subsequently centrifuged for 20 min at 40,000 xg at 4°C using a 
Beckman Coulter Avanti JXN-26 centrifuge with a JA-25.25 rotor. Supernatant was 
discarded, and the pellet was re-suspended in 10 mL ice-cold buffer B (10 mM 
HEPES, 10 mM EDTA, pH 7.4). The pellet was homogenised, GTP (1 mM final) was 
added and the suspension was incubated at 37°C for 15 min. The suspension was 
subsequently centrifuged for 20 min at 40,000 xg at 4°C and the pellet was re- 
suspended in 15 mL ice-cold buffer C (10 mM HEPES, 0.1 mM EDTA, pH 7.4) and 
re-homogenised as before. Suspension was centrifuged again for 20 min at 40,000 
 39 
xg at 4°C. The final pellet was re-suspended in buffer C and protein concentration 
was estimated using a Bradford assay. The homogenate was then further diluted in 
final storage buffer to produce a concentration of 2 mg/ml.  
[35S]-GTPγS binding and immunoprecipitation of Gα subunits was performed as 
previously described 1 .  Specifically, M1-WT, M1-DREADD, M1-PD or M1-DREADD 
PD membranes were diluted in assay buffer (in mM: HEPES, 10; NaCI, 100; MgCl2, 
10; pH 7.4) containing a final concentration of 1 μM GDP. Membranes (75 μg in a 
total assay volume of 200 μL) were added to [35S]-GTPγS (1 nM final concentration) 
and agonists (CCh or CNO) and incubated at 30°C for 5 min. Reactions were 
terminated by the addition of 1 mL ice-cold assay buffer and immediate transfer to an 
ice bath. Samples were centrifuged (20,000 xg, 6 min, 4°C) and membrane pellets 
solubilised by the addition of 50 μL ice-cold solubilisation buffer (100 mM Tris HCI, 
200 mM NaCI, 1 mM EDTA, 1.25% Igepal and 0.2% SDS, pH 7.4) and incubation for 
1 h at 4°C on a shaking platform. Following complete protein re-solubilisation, 50 μL 
of solubilisation buffer without SDS was added. Solubilised protein was pre-cleared 
using normal rabbit serum at a dilution of 1:100 and 3% (w/v) protein A-sepharose 
beads in TE buffer (10 mM Tris HCI, 10 mM EDTA, pH 8.0) added for 60 min at 4°C. 
Protein A- sepharose beads and insoluble material were collected by centrifugation 
(20,000 xg, 6 min, 4°C) and 100 μL of the supernatant was transferred to fresh tubes 
containing Gq-specific anti-serum (Santa Cruz; sc393) and incubated overnight at 
4°C. Protein A-sepharose beads were added to samples, vortex mixed and rotated 
at 4°C for 90 min before being centrifuged (10,000 xg, 1 min, 4°C). Supernatants 
were aspirated and the protein A- sepharose beads washed three times with ice-cold 
solubilisation buffer (without SDS). Recovered beads were then mixed with 1 mL 
FloScint-IV scintillation cocktail and counted by liquid scintillation spectrometry.  
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Ins(1,4,5)P3 mass assay 
M1-HA or M1-PD mice were humanely killed via cervical dislocation. The brain was 
exposed transferred to an ice-cold platter and cerebral cortex dissected.  Cerebral 
cortex was cross-chopped using a McIlwain tissue chopper (300 μm x 300 μm).  The 
resulting tissue cubes were dispersed into Krebs-Henseleit buffer (KHB (in mM): 
NaCl, 118; KCl, 4.7; MgSO4, 1.2; NaHCO3, 25; NaH2PO4, 1.2; CaCl2, 1.3; HEPES, 
10; glucose, 11; pH 7.4 after equilibration with O2/CO2 95:5), washed by multiple 
buffer changes and then shaken in an oscillating water bath for 60 min at 37oC; 
tissue cubes were sedimented under gravity and buffer changed every 10 min during 
this period. 
 
At the end of the washing period cerebral cortex cubes were allowed to sediment 
under gravity and 25 μL aliquots of ‘packed’ tissue transferred to a flat-bottomed 5 
mL tube containing 250 μL KHB.  Each tube was purged with O2/CO2 (95:5), capped 
and returned to a shaking water bath at 37oC.  Drug additions were made (bringing 
the total incubation volume to 300 μL), tubes again purged with O2/CO2 (95:5) and 
incubations continued for the times indicated in figure legends.  Incubations were 
terminated by addition of an equal volume of ice-cold 1 M trichloroacetic acid and 
tubes allowed to extract on ice for 30 min.  Tubes were then centrifuged (2,000 xg, 
20 min, 4oC).  Supernatants were recovered, neutralised using the 
dichlorodifluoromethane/tri-n-octylamine method and inositol 1,4,5-trisphosphate 
(IP3) concentration was determined exactly as described previously2.  Tissue cube 
pellets were solubilized by addition of 1 M NaOH.  Protein concentration was 
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determined for each incubation using the Lowry method.  This allowed IP3 mass 
accumulation to be expressed as pmol IP3 mg-1 protein.  
 
Elevated plus maze 
The mice were habituated to the EPM testing room overnight and were maintained in 
the dark until testing. Where mice received vehicle (5% glucose) or CNO (0.3 
mg/kg), this was administered 30 min prior to the test via intraperitoneal (i.p.) 
injection. 
 
The elevated plus maze (EPM) consisted of four non-transparent arms (50 x 10cm); 
two enclosed arms (with black walls of 30cm height), and two dimly illuminated open 
arms.  Mice were placed into the centre of the elevated plus maze, facing the closed 
arm. Mice were tracked using ANY-maze software for 5 min, and the number of 
entries into the closed or open arms during this time was monitored. Anxiety level 
was calculated as a percentage of open arm entries versus total entries made. The 
maze was cleaned with 70% ethanol between each animal.  
 
Open field 
General locomotor activity was assessed using the open field test, following 
overnight habituation in the behavioural testing suite. Mice were placed into a clear, 
Perspex square arena (50 x 50 cm) and activity was tracked for a 10 min period 
using ANY-maze software. 
 
Y maze 
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Mice were habituated to the behavioural testing suite overnight prior to the test. For 
tests where mice received vehicle (5% glucose) or CNO (0.3 mg/kg), these were 
administered via i.p. injection 30 min prior to the start of the test. Mice were placed 
into the centre of a Y maze (grey, non reflective base plate) with three identical arms 
(A, B, C; lane width: 5 cm; arm length: 35 cm; arm height: 10cm). Activity was 
recorded using ANY-maze software. Spontaneous alternation behaviour was 
calculated by measuring the number of “ABC” sequences (in any order) as a 
proportion of the total triplet sequences made during the 8 min test.   
 
In vivo telemetry 
The basal locomotor activity was measured in intact freely moving WT, M1-PD and 
M1-KO mice by telemetric system (Data Sciences International, St Paul, MN, USA). 
The TA-F10 implantable probes (1.1 cc; 1.6 grams) were implanted in the peritoneal 
cavity under the isoflurane (1.5-2%) anaesthesia and carprofen (Rimadyl®; 5 mg/kg 
s.c.) analgesia. During the implantation, the mice were kept on the thermostable pad. 
After the surgery, mice were housed individually and left 1 week for recovery before 
being used in the experiment. Basal locomotor activity was acquired directly from the 
transponders for three consecutive days during which the animals were not 
disturbed. Locomotor activity was recorded in home cages. Receivers were 
connected through MX2 matrix directly to the PC into a single computer port, 
allowing for the determination of all parameters. The data were collected every 
60 sec and Ponemah® acquisition system (DSI) was used for collecting and first 
processing of data.  
 
Biorhythm analysis 
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The data from telemetry experiment collected by Ponemah® acquisition system (DSI) 
were grouped into 10 min sequences, and the calculated means were used for 
further analysis. The analysis was performed using the ChronosFit program3 
employing Fourier analysis and the stepwise regression technique.  
 
EEG recordings 
Surgery and recording 
Animals (M1-HA WT, M1-DREADD, M1-MDREADD PD) were anesthetised with 
isoflurane (1–1.5%) and placed in a stereotaxic frame (model SR-5M-HT; Narishige, 
Japan). Animals’ head were shaved using electric clippers and cleaned with ethanol 
(70%) and iodopovidone. Lidocaine (2%, 0.1–0.3 mg) was administered 
subcutaneously at the site of incision and carprofen (Rimadyl®; 5 mg/kg) was 
administered subcutaneously to provide analgesia after the surgery. The body 
temperature of animals was maintained at 37°C using a heating pad during the 
entire surgery. Five bone screws were fixed in the skull, two in the frontal region (AP 
+1.5 mm, ML ± 1 mm from bregma) used as electrodes for frontal cortical 
electroencephalograms (EEGs), two in the parietal region (AP - 2 mm, ML ± 2 mm 
from bregma) used for parietal cortical EEGs and one on the cerebellum as a ground 
and a reference. Then the electrodes with screws were attached with dental cement 
as a head-post. After the head-post surgery the animals were left to recover for at 
least 5 days before using in the experiment. During an acclimation period of 5 days, 
the animals were on daily basis handled, placed in recording chamber and the 
animal’s head was tethered to the recording cable. The following day after the 
acclimation period, the animals were placed back in the recording chamber for 
electrophysiological recording.  
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The recording was performed as followed. The initial 15 min served for the recording 
of basal cortical activity. Then, mice were injected (i.p.) with vehicle (5% glucose) or 
with CNO (0.3 mg/kg) and EEGs recording continued for another 45 (75) min. During 
the whole experimental procedure, mice were allowed to freely move and were 
monitored for the occurrence of seizures. 
 
After animals were anesthetised with isoflurane (1 - 1.5%), they were placed in a 
stereotaxic frame (SR-5M-HT, Narishige) and body temperature was retained at 
37°C using a feedback temperature controller (50-7221-F, Harvard Bioscience, Inc.). 
Lidocaine (2%, 0.1 ml) was administered subcutaneously at the site of incision and 
Carprofen (Rimadyl, 5 mg/kg) was also administered subcutaneously at the back. 
After incision, the skull was exposed and cleaned. Four bone screws were implanted 
and used for cortical electroencephalogram (EEG) recording. Another screw was 
implanted over the cerebellum as a ground and a reference. All screws were 
connected with a connector and covered with dental cement. The animals were left 
to recover for at least 5 days.  
 
Electrophysiological recording procedures are described elsewhere 3-4 Briefly, the 
animal was placed in an open box (21.5 cm x 47 cm x 20 cm) by connecting a 16-
channel amplifier board (RHD2132, Intan Technologies, LLC) and an interface cable. 
Signals were amplified relative to a cerebellar bone screw and were digitized at 1000 
Hz (RHD2132 and RHD 2000, Intan Technologies, LLC). Each recording session 
consisted of a 15-min baseline recording, an intraperitoneal injection (CNO, 0.3 
mg/kg or vehicle), and another recording for at least 45 min.  
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All offline analysis was performed using MATLAB (version R2018b, Mathworks). 
Because all four EEG channels provided qualitatively similar signals, only the signals 
at the right frontal region were used. To compute spectrogram, the multi-taper 
spectral estimation method was applied (Chronux Toolbox, http://chronux.org/). To 
evaluate signal power, root-mean-square (RMS) value was computed in every 1 sec 
and scaled in dB. After lowpass-filtering the scaled signals at 1/300 Hz, they were 
normalized relative to the baseline (the mean value of first 5 min signals) to compare 
them across experiments.    
 
Measurement of saliva secretion 
Mice were anesthetised by i.p. injection with 100 mg/kg of ketamine/0.25 mg/kg of 
medetomidine. Following this procedure, mice were injected with pilocarpine (1 
mg/ml, i.p.) and salivary secretion (in milligrams of saliva) onto GF/B filter paper (GE 
Healthcare Life Sciences) was recorded every 5 min over a 35 min period. 
 
Immunocytochemistry for internalisation of receptors 
CHO cells stably expressing HA-tagged (C-terminal) version of the mouse M1-WT, 
mouse M1-PD, humanized M1-DREADD or humanized M1- DREADD PD were 
grown for 24 h to achieve 60-80% confluence on 13 mm glass coverslips coated with 
0.01% Poly-D-Lysine. Cells were stimulated with 100 µM carbachol (WT and M1-PD) 
or CNO (M1-DREADD or M1-DREADD PD) for 1 h, fixed using 4% PFA (in TBS 
buffer), and blocked and permeabilised using 2% BSA in Triton X-100 (0.1% in TBS 
buffer). Incubation with anti-EEA1 polyclonal antibody (ThermoFisher Scientific; 
1:1000) was carried out at 4°C overnight, and incubation with anti-HA antibody 
(Roche; 1:1000) was performed at room temperature for 2 h. Following three washes 
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with TBS buffer, secondary antibody incubation with AlexaFluor 594 anti-rabbit and 
AlexaFluor 488 anti-rabbit (Thermo Fisher; 1:400) was performed for 2 h at room 
temperature, and followed by three quick washes with TBS. Coverslips with stained 
cells were mounted on glass slides using VECTASHIELD HardSet Antifade 
Mounting Medium with DAPI. Data were acquired using a LSM 880 confocal laser 
scanning microscope (Zeiss). 
 
Rat IP accumulation 
Sample Collection  
Rat (Sprague-Dawley 250-275g) brain samples (frontal cortex) were collected after 
animals were administered the following treatments: H2O vehicle or LiCl (100mg/kg, 
sc) followed 30 min later by H2O vehicle or scopolamine (1mg/kg, s.c.) or SKF38393 
(20 mg/kg, s.c.) at a dose volume of 1 ml/kg. One hour post LiCl administration rats 
were dosed with pilocarpine (10, 30, or 100 mg/kg, s.c.) or GSK1034702 (3, 10, or 
30mg/kg, i.p.). Rats were then sacrificed 2 hours later and frontal cortex collected 
over dry ice. Samples were stored at -70°C for LC/MS/MS analysis of inositol 
phosphate. 
 
Mass Spectrometry 
Samples were homogenized using a probe sonicator set at level 8 for 10 sec in 5x 
volumes of 50% acetonitrile containing 0.1% formic acid and 50% methanol (MeOH). 
Samples were then centrifuged for 12 min at 13000 x g. 100 ul of supernatant was 
transferred into 200 ul of distilled water and 20ul aliquots of samples were injected 
onto LC/MS apparatus. Myo-Inositol 2-monophosphate bis (cyclohexylammonium) 
salt (Sigma Aldrich - I5250) was used to prepare standards (10, 30, 100, 300 and 
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1000ng/g or ml) in 50% acetonitrile + 50% methanol + 0.1% formic acid). The 
analysis of inositol phosphate (IP) was carried out using an Agilent 6410 series triple 
quad LC/MS/MS with MassHunter data analysis software (Agilent Technologies Inc, 
Santa Clara, CA 95051 U.S.A.) fitted with an electrospray ion source and run in 
negative mode.  Detection was accomplished by monitoring the precursor ion of IP 
with mass to charge ratio (m/z) of 259 and targeting its product ion with m/z set to 
78.9. The chromatographic separation employed a Zorbax RX-SIL HPLC Column, 
2.1 X 150mm from (Agilent Technologies Inc, Santa Clara, CA 95051 U.S.A.) and a 
mobile phase consisting of 3% acetonitrile in water with an overall 0.1% formic acid 
content with a flow rate of 0.7mL per minute.  Clearly delineated chromatographic 
peaks with the retention time of authentic standards and expected molecular weight 
were seen after each injection of sample. Analyte were quantified based on the 
areas of these peaks. 
 
In vivo receptor occupancy 
Live Phase 
Male Sprague-Dawley rats (N=4 per dose group) were purchased from Harlan 
(Indianapolis) and ranged in weight from 200-300 g. Pilocarpine or GSK1034702 
were administered at doses of 0.03, 0.1, 0.3, 1, 3 and 10 mg/kg for generation of a 
dose-response. Animals received either vehicle alone (1% Hydroxyethlycellulose, 
0.25% Polysorbate 80, 0.05% Antifoam in purified water) or test compound in a dose 
volume of 10 ml/kg.  In the dose response studies, rats received i.v. administration of 
non-labelled tracer LSN3172176 5 10 mg/kg, 0.5 ml/kg dose volume for rats and 5 
ml/kg dose volume for mice; in the lateral tail vein 30 min after vehicle or compound 
administration.  Animals were sacrificed by cervical dislocation 20 min after tracer 
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administration. Brains were removed and dissected. Frontal cortex and cerebellum 
were used for the tracer measurement and the remaining brain and plasma used for 
compound exposure analysis. The receptor occupancy is considered to be 
measured at the time of tracer administration (t). Studies were performed at Covance 
Alnwick or Greenfield.   
 
Tissue Preparation and Tracer Analysis 
Frontal cortex and cerebellar samples were weighed and placed in conical centrifuge 
tubes on ice.  Four volumes (w/v) of acetonitrile containing 0.1% formic acid was 
added to each tube. Samples were then homogenized using an ultrasonic probe and 
centrifuged using a bench top centrifuge at 14,000 RPM for 20 min.  Supernatant 
was diluted by adding 50 µL to 150 µL sterile water in 96-well plates for LC/MS/MS 
analysis. Analysis of LSN3172176 was carried out using an API 4000 mass 
spectrometer.  Chromatographic separation employed an Agilent Zorbax Eclipse 
XDB-C18 column (2.1 X 50 mm) and a gradient mobile phase consisting of 15% to 
90% acetonitrile in water with an overall 0.1% formic acid content.  Detection of 
LSN3172176 was accomplished by monitoring the precursor to product ion transition 
with a mass to charge ratio (m/z) of 386.3 to 128.0.  Standards were prepared by 
adding known quantities of the tracer to brain tissue samples from non-treated rats 
or mice and processing as described above. 
 
Receptor Occupancy Determinations 
Receptor occupancy was calculated using the ratio method.  The level of tracer was 
measured in each cortical and cerebellar sample.  A ratio of cortical levels (total 
binding) to cerebellar levels (nonspecific binding) was generated for each animal.  
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Vehicle ratios represent 0% occupancy and a ratio of 1, where the binding in the 
cortex is equal to the binding in the cerebellum, represents 100% occupancy. The 
ratios from the pilocarpine and GSK1034702 pretreated groups were interpolated 
linearly between the ratio in the vehicle-treated animals (0% occupancy) and 1 
(100% occupancy) in order to determine the percent M1 receptor occupancy. For the 
pilocarpine and GSK1034702 dose response, a curve was fitted to a 4-parameter 
logistic function with the bottom and top fixed at 0% and 100%, respectively using 
GraphPad Prism version 6.0 and the dose achieving 50% receptor occupancy 
(RecOcc50) was calculated by the software.  Values are given as mean ± S.E.M. 
 
For conversion of total plasma or brain levels to unbound levels, the % values for 
SPP1 free in the plasma (4.4%) and brain (10.1%) were used. The unbound brain to 
unbound plasma concentration ratio is the KP,uu, where Kp is the total brain to total 
plasma concentration ratio and uu stands for unbound brain and plasma 
 
Data analysis 
Functional concentration-response curves were fitted according to a four-parameter 
logistic equation (to determine minimum and maximum asymptotes, LogEC50, and 
slope; GraphPad Prism 6). To assess agonist bias, the same concentration-
response curves were analyzed according to a modified form of the operational 
model of agonism, recast to directly yield a transduction ratio (Log[τ/KA];6): where 
basal represents the response in the absence of agonist, Em represents the maximal 
response of the assay system, KA represents the equilibrium dissociation constant of 
the agonist, [A] represents the concentration of agonist, τ is an index of the coupling 
efficiency (or efficacy) of the agonist, and n is the slope of the transducer function 
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linking agonist occupancy to response. For the analysis, all families of agonist curves 
at each pathway were globally fitted to the model with the parameters, basal, Em, 
and n shared between all agonists. For full agonists, the LogKA was constrained to a 
value of zero, whereas for partial agonists this was directly estimated by the curve 
fitting procedure; the Log(τ/KA) parameter was estimated as a unique measure of 
activity for each agonist. Agonist bias factors (10^DDLog[τ/KA]) were calculated as 
previously described6.  
 
Data availability statement: All data is available from the 
authors or is available through the University of Glasgow online data repository 
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